Articles tagged with Cancer Patients
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
In a Phase I clinical trial, sotorasib achieved a confirmed response rate of 32.2% and disease control rate of 88.1% in patients with KRAS G12C-mutant non-small cell lung cancer, with durable clinical benefits and manageable toxicities
A UC study found that patients with cancer who contract COVID-19 have a higher risk of death if treated with certain anti-cancer therapies at specific times. The study analyzed data from over 3,000 patients and found that those treated one to three months prior to diagnosis had the highest mortality rates.
A phase III clinical trial led by Queen Mary University of London shows that immunotherapy drug avelumab significantly improves survival in patients with the most common type of bladder cancer. Avelumab resulted in a 31% reduction in risk of death and extended median survival by over seven months.
A study found that using proton pump inhibitors (PPIs) worsened survival rates and disease progression in patients with urothelial cancer treated with atezolizumab. PPI use did not affect overall survival or response to chemotherapy.
A single-center observational study found that PET/MRI improves lesion detectability in select cancers and significantly reduces overall radiation exposure compared to PET/CT. The study, published in The Journal of Nuclear Medicine, shows that PET/MRI can promote fast, efficient local and whole-body staging in one step.
A team of researchers developed a mathematical model that can determine the impact of the immune system on tumour evolution. The model predicts when cancer cells will activate their cloaking mechanisms against the immune system and informs on whether immunotherapy is likely to be effective.
A clinical trial is underway to test psilocybin therapy for depression in cancer patients. The study aims to investigate the combination of individualized treatment and group administration to provide long-term relief from depression symptoms.
A new study finds that high viral loads are associated with a greater risk of death among patients with both cancer and COVID-19. Patients with hematologic malignancies who had recently been treated for cancer had the highest levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Smokers have worse chemotherapy response and higher mortality rates from bladder cancer, with a higher risk of cancer recurrence. Former smokers also fare poorly in these categories.
A new biomarker has been identified that reliably predicts the aggressiveness of biliary tract cancer in patients, which could help doctors make informed decisions about chemotherapy. The biomarker, IL-6, has been shown to provide prognostic information not captured by other inflammatory markers already in use.
The University of Louisville will establish a Center for Cancer Immunology and Immunotherapy to develop and improve cancer treatments that utilize the immune system. Researchers will focus on advancing strategies to use the immune response to fight cancer, with the goal of saving lives through immunotherapies.
Researchers at Ohio State University have discovered that RNA nanoparticles exhibit elastic and rubbery properties, enabling them to target tumors by slipping through tumor blood vessels. The particles are also excreted from the body quickly via urine, reducing toxicity.
A preclinical study from MD Anderson and BridgeBio's Navire Pharma shows that SHP2 inhibition can overcome osimertinib resistance in lung cancer. The study found that IACS-13909 suppressed tumor cell proliferation and caused tumor regression in various activated kinase-driven models.
Researchers at Case Western Reserve University are developing a novel technique using nanotechnology to wake up 'cold' tumors, allowing immune cells to locate and neutralize them. The approach aims to improve treatment outcomes for metastatic breast cancer patients by combining nanotechnology with immunotherapy.
The COVID-19 pandemic has resulted in a huge backlog of cancer treatments and research, with delays and cancellations reported across 18 countries. Oncology professionals are also facing burnout and wellbeing damage due to the pandemic's impact on their workload and job performance.
Researchers at Huntsman Cancer Institute discovered that HIF-1α is linked to aggressive tumors, metastasis, and poor patient survival, while HIF-2α is associated with less aggressive tumors and better outcomes. The study suggests a potential new paradigm for understanding kidney cancer.
A Phase II trial found that a combination of ipilimumab and nivolumab generated durable responses in 25% of patients with metastatic castration-resistant prostate cancer. The treatment achieved disease control in 46.9% of patients, with median progression-free survival of 5.5 months.
Researchers found that 27% of immune checkpoint inhibitor recipients experienced irAEs, with 5% developing multi-organ irAEs sequentially. Multi-organ irAEs were generally amenable to satisfactory management and associated with better overall survival rates.
A program using mail-in stool samples is shown to be an effective and cost-effective alternative to in-person colonoscopies for detecting colon cancer. The study identified nine best practices for implementing such programs, including patient navigation and high-quality testing kits.
Researchers developed a statistical model using genomic data to predict risk of developing oesophageal cancer in patients with Barrett's oesophagus. The model accurately identified high-risk patients years before diagnosis, allowing for early treatment and reducing unnecessary surveillance.
A five-year grant will follow over 2,000 testicular cancer survivors to examine the role of genetic variants in platinum toxicities and assess the impact on physical, emotional, and social functioning. The study aims to identify high-risk subgroups and provide guidelines to decrease damaging side effects.
A University of Cincinnati researcher is studying how cancer treatments could impact patients who also have COVID-19 and blood clots. The study aims to understand the thrombotic risk posed by certain cancer treatments and hopes to contribute data that could prevent complications for millions of patients.
A retrospective analysis found that Black pediatric patients are less likely to receive proton therapy, which may lead to increased side effects and long-term health disparities. The study calls for addressing barriers to access and promoting equitable distribution of this high-cost treatment.
Researchers developed a prognostic tool that identifies immune cell interactions with tumour cells and reports on immune-checkpoint activation status. The tool predicts which cancer patients are most likely to benefit from checkpoint inhibitor therapy, allowing clinicians to tailor treatments specifically to patients.
The partnership aims to galvanize the global research community to make transformative leaps in cancer research. Researchers will be encouraged to think creatively and act boldly to address major challenges in understanding cancer.
Researchers from Kanazawa University found that IL-17A triggers cellular changes in the peritoneum, leading to stromal fibrosis in gastric cancer patients. The study suggests that suppressing mast cell degranulation may be a promising treatment strategy for patients with peritoneal dissemination.
The Herbert Irving Comprehensive Cancer Center has been renewed as a designated Comprehensive Cancer Center by the National Cancer Institute, with a five-year support grant of $26.5 million. The center will continue to provide cutting-edge care and research for cancer patients in the New York City metropolitan area.
Researchers have identified a metabolic vulnerability in cells that may represent a therapeutic target for treating small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). A new treatment agent has been shown to starve cancer cells by eliminating arginine, an amino acid necessary for protein production.
The Phase I/II LIBRETTO-001 trial found that selpercatinib achieved durable objective responses in the majority of participants with RET gene fusions, including an ORR of 85% in previously untreated patients. The study also showed promising results in patients with brain metastases and thyroid cancers.
Prof. Hans-Joachim Schmoll receives the ESMO Award 2020 for his pioneering work in developing medical oncology as a specialty, while Prof. Nadia Harbeck wins the Lifetime Achievement Award for her global cancer research and education contributions.
A new device developed by Dartmouth engineers has the potential to improve patient outcomes for prostate cancer patients who undergo radical prostatectomy. The device, which uses microendoscopic electrical impedance sensing probe technology, aims to detect positive surgical margins and prevent disease recurrence.
Researchers have developed a novel STAR assay to measure absolute telomere length, enabling rapid diagnosis of cancer and age-related diseases. The method can process up to 48 samples from low DNA amounts, providing critical information for precision therapy.
Researchers at Thomas Jefferson University have developed a cancer vaccine that shows promise in treating gastric, pancreatic, esophageal, and colon cancers. The new vaccine, Ad5.F35, is more effective than the original version due to its ability to evade the immune system's natural defenses.
The European Society for Medical Oncology has issued its first recommendations on the use of next-generation sequencing (NGS) for patients with metastatic cancers. The guidelines recommend routine NGS use for four specific cancer types, while also allowing patients to order larger gene panels if feasible and cost-effective. The recomme...
The National Cancer Institute (NCI) and Cancer Research UK will establish the Cancer Grand Challenges program to tackle cancer research challenges. The initiative aims to facilitate global collaboration, foster innovation, and accelerate progress against cancer.
A Cedars-Sinai study found that robotic surgery for oropharyngeal cancer is associated with improved health outcomes, including better long-term survival rates and reduced risks of positive surgical margins. The procedure's increased use since FDA approval in 2009 was linked to these benefits.
A new database of 40 breast cancer cell lines will help speed the development of new gene-targeted therapies by providing genomic and proteomic information. Researchers aim to identify functional genes that drive cancer growth and develop targeted therapies based on unique gene changes in each patient's cancer.
Researchers discovered that removing copper from blood can destroy some deadly cancers resistant to immunotherapy. High levels of copper in cancer cells increase expression of PD-L1, a protein that hides cancer cells from the immune system.
A recent survey of UK professionals found that COVID-19 has caused significant disruptions to psycho-social care for cancer patients, leading to delays in accessing support. The study highlights the need for innovative solutions to address the growing demand for psychological support during the pandemic.
A recent study found that extrachromosomal DNA (ecDNA) is common in human cancer and drives poor patient outcomes. ecDNA is a circular unit of DNA containing functional genes located outside cells' chromosomes, which rapidly replicate within cancer cells causing high numbers of oncogene copies.
A Phase II trial conducted at the University of Texas M. D. Anderson Cancer Center found a 51% overall response rate in patients with BRAF-mutated cholangiocarcinoma treated with dabrafenib plus trametinib, providing a much-needed treatment option for patients with treatment-resistant advanced disease.
A new liquid biopsy test has been developed to detect cancer by analyzing protein biomarkers from tumors in the blood. The study found that this approach showed a high sensitivity and specificity for detecting different types of cancer, including breast, colon, and lung cancers.
A study examined the association between radiotherapy timing and overall survival in patients with prostate cancer. The analysis of National Cancer Database data found that delaying radiotherapy relative to androgen deprivation therapy was associated with improved overall survival.
The COVID-19 pandemic worsens existing health disparities in cancer patients, with marginalized communities facing poorer treatment outcomes. Healthcare providers must acknowledge these disparities to deliver equitable care.
A Phase III trial led by the University of Texas MD Anderson Cancer Center found that combining venetoclax and azacitidine improved overall survival and achieved a 66.4% complete remission rate in patients with acute myeloid leukemia.
Recent advances in treatment have led to a sharp reduction in lung cancer mortality rates in the US, with non-small cell lung cancer deaths decreasing faster than incidence. The study found significant improvements in survival for both men and women, particularly after the introduction of targeted therapies.
A Singapore team identified a mutation in the PD-L1 gene as a reliable biomarker for patients with natural-killer T-cell lymphoma who are likely to respond positively to anti-PD-1 therapy. The study found an overall response rate of 47% and complete responses in 7 out of 19 patients.
The new guidelines offer additional recommendations for photobiomodulation therapy and benzydamine, as well as a stronger guideline statement for cryotherapy. Researchers also found that natural honey may help prevent mucositis in head and neck cancer patients, although long-term effects are unclear.
A new study shows that men treated for testicular cancer at public safety net hospital and academic tertiary care center have the same outcomes, despite differences in demographics. The study eliminated sociodemographic disparities in survival and cancer recurrence rates.
A qualitative study proposes a practical communication guide to assuage the fear, anger and anxiety of cancer patients during the COVID-19 pandemic. The guide aims to improve patient care in oncology settings.
A team of researchers at Michigan Medicine developed a guide to help oncologists navigate difficult conversations with patients due to the pandemic. The guide provides three core communication strategies and examples of language that can be used to respond empathetically, addressing concerns around risk, delays, and changes in treatment.
Researchers at Ohio State University Comprehensive Cancer Center have found that molecular characteristics can refine prognostic recommendations for AML patients under age 60. The study detected mutations in several categories, which were associated with better or worse outcomes and may help improve treatment choices.
A rapid and affordable test for breast cancer has been developed to combat delayed diagnoses in developing regions. The compact CytoPAN test uses image cytometry to analyze individual cells, yielding results in under 1 hour and requiring minimal training, making it ideal for resource-limited settings.
Researchers at Huntsman Cancer Institute develop new models to study molecular characteristics of lung and pancreas tumors driven by NTRK1 mutations. The findings aim to identify effective treatments for patients with NTRK1-driven cancers, which have proven resistant to current therapies.
The COVID-19 pandemic has led to changes in the number of new cancer diagnoses in US patients. Researchers analyzed data from 2020 and found that there was a significant increase in new cases during the pandemic.
Dr. Emmanuel Katsanis is studying a new chemotherapy treatment for patients with blood-related cancers who undergo a specific type of bone marrow transplant procedure. The treatment, known as haploidentical BMT, has shown promising results in improving survival rates and reducing post-transplant complications.
A blood test can predict which cancer patients will benefit from immunotherapy, a treatment option for advanced cancers. The test analyzes changing levels of tumour fragments in the blood to identify those who will respond well to the treatment.
A large international study analyzed genetic and clinical data from 4,444 MDS patients to assess the impact of TP53 gene mutations on cancer outcomes. The study found that having two mutated copies of TP53 led to worse outcomes, while one copy had similar effects as a non-mutated copy.
Cancer patients at low risk of severe COVID-19; treating cancer can impact overall survival. ESMO recommends continuing anti-cancer treatments to prioritize tumour control.
A new study by NYU Langone Health found that women receiving standard treatment for ovarian, uterine, and cervical cancers are not at increased risk of hospitalization or death from COVID-19. In fact, 75% of gynecologic cancer patients with COVID-19 had a mild form of the disease and recovered